NUVALENT INC-A (NUVL) Fundamental Analysis & Valuation

NASDAQ:NUVL • US6707031075

Current stock price

96.15 USD
-0.28 (-0.29%)
At close:
96.14 USD
-0.01 (-0.01%)
Pre-Market:

This NUVL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NUVL Profitability Analysis

1.1 Basic Checks

  • NUVL had negative earnings in the past year.
  • In the past year NUVL has reported a negative cash flow from operations.
  • NUVL had negative earnings in each of the past 5 years.
  • NUVL had a negative operating cash flow in each of the past 5 years.
NUVL Yearly Net Income VS EBIT VS OCF VS FCFNUVL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • NUVL's Return On Assets of -30.11% is fine compared to the rest of the industry. NUVL outperforms 66.86% of its industry peers.
  • The Return On Equity of NUVL (-34.08%) is better than 72.06% of its industry peers.
Industry RankSector Rank
ROA -30.11%
ROE -34.08%
ROIC N/A
ROA(3y)-23.39%
ROA(5y)-20.58%
ROE(3y)-25.49%
ROE(5y)-22.08%
ROIC(3y)N/A
ROIC(5y)N/A
NUVL Yearly ROA, ROE, ROICNUVL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NUVL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVL Yearly Profit, Operating, Gross MarginsNUVL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

8

2. NUVL Health Analysis

2.1 Basic Checks

  • NUVL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NUVL has been increased compared to 5 years ago.
  • There is no outstanding debt for NUVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NUVL Yearly Shares OutstandingNUVL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
NUVL Yearly Total Debt VS Total AssetsNUVL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • An Altman-Z score of 26.77 indicates that NUVL is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of NUVL (26.77) is better than 92.29% of its industry peers.
  • There is no outstanding debt for NUVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.77
ROIC/WACCN/A
WACCN/A
NUVL Yearly LT Debt VS Equity VS FCFNUVL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 15.27 indicates that NUVL has no problem at all paying its short term obligations.
  • NUVL has a better Current ratio (15.27) than 92.87% of its industry peers.
  • NUVL has a Quick Ratio of 15.27. This indicates that NUVL is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 15.27, NUVL belongs to the best of the industry, outperforming 92.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.27
Quick Ratio 15.27
NUVL Yearly Current Assets VS Current LiabilitesNUVL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1

3. NUVL Growth Analysis

3.1 Past

  • NUVL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 23.72% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.2%
EPS Next 2Y10.34%
EPS Next 3Y20.04%
EPS Next 5Y23.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NUVL Yearly Revenue VS EstimatesNUVL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
NUVL Yearly EPS VS EstimatesNUVL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

1

4. NUVL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NUVL. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVL Price Earnings VS Forward Price EarningsNUVL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVL Per share dataNUVL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • NUVL's earnings are expected to grow with 20.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.34%
EPS Next 3Y20.04%

0

5. NUVL Dividend Analysis

5.1 Amount

  • No dividends for NUVL!.
Industry RankSector Rank
Dividend Yield 0%

NUVL Fundamentals: All Metrics, Ratios and Statistics

NUVALENT INC-A

NASDAQ:NUVL (3/24/2026, 8:00:02 PM)

Premarket: 96.14 -0.01 (-0.01%)

96.15

-0.28 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners108.94%
Inst Owner Change7.01%
Ins Owners0.59%
Ins Owner Change2.24%
Market Cap7.56B
Revenue(TTM)N/A
Net Income(TTM)-425.38M
Analysts85.83
Price Target142.67 (48.38%)
Short Float %7.98%
Short Ratio10.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.18%
Min EPS beat(2)-21.37%
Max EPS beat(2)-4.98%
EPS beat(4)0
Avg EPS beat(4)-10.82%
Min EPS beat(4)-21.37%
Max EPS beat(4)-4.98%
EPS beat(8)2
Avg EPS beat(8)-10.66%
EPS beat(12)5
Avg EPS beat(12)-5.41%
EPS beat(16)8
Avg EPS beat(16)-2.96%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.09%
EPS NQ rev (1m)8.54%
EPS NQ rev (3m)8.54%
EPS NY rev (1m)3.84%
EPS NY rev (3m)3.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-35.36%
Revenue NY rev (3m)-34.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.06
P/tB 6.06
EV/EBITDA N/A
EPS(TTM)-5.85
EYN/A
EPS(NY)-5.66
Fwd EYN/A
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.5
OCFYN/A
SpS0
BVpS15.88
TBVpS15.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.11%
ROE -34.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.39%
ROA(5y)-20.58%
ROE(3y)-25.49%
ROE(5y)-22.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.27
Quick Ratio 15.27
Altman-Z 26.77
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50.48%
EPS Next Y3.2%
EPS Next 2Y10.34%
EPS Next 3Y20.04%
EPS Next 5Y23.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.89%
EBIT Next 3Y24.01%
EBIT Next 5Y25.98%
FCF growth 1Y-48.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.71%
OCF growth 3YN/A
OCF growth 5YN/A

NUVALENT INC-A / NUVL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NUVALENT INC-A (NUVL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NUVL.


Can you provide the valuation status for NUVALENT INC-A?

ChartMill assigns a valuation rating of 1 / 10 to NUVALENT INC-A (NUVL). This can be considered as Overvalued.


What is the profitability of NUVL stock?

NUVALENT INC-A (NUVL) has a profitability rating of 1 / 10.


Can you provide the financial health for NUVL stock?

The financial health rating of NUVALENT INC-A (NUVL) is 8 / 10.